530 related articles for article (PubMed ID: 25057302)
1. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
Paplomata E; O'Regan R
Ther Adv Med Oncol; 2014 Jul; 6(4):154-66. PubMed ID: 25057302
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
3. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
du Rusquec P; Blonz C; Frenel JS; Campone M
Ther Adv Med Oncol; 2020; 12():1758835920940939. PubMed ID: 32782489
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
7. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.
; ;
Cancer Innov; 2022 Jun; 1(1):25-54. PubMed ID: 38089455
[TBL] [Abstract][Full Text] [Related]
8. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
9. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
Yi Z; Ma F
J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
[TBL] [Abstract][Full Text] [Related]
11. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
12. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
13. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
14. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
16. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK
Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]